At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy
In Brief
A Phase 3 clinical trial evaluating SHR-1210, Apatinib, and 1 other intervention for Locally Advanced or Metastatic and Unresectable HCC. Completed, enrolled 543 participants across 121 sites in 13 countries.
Detailed Summary
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
Study Details
Timeline
Interventions
Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet